Date: 2016-01-11
Type of information: Nomination
Compound:
Company: Medivation (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 11, 2016, Medivation announced that Marion McCourt will join the company as chief operating officer on February 1, 2016. In this newly created position, Ms. McCourt will be responsible for oversight of several functions including commercial operations, medical affairs, manufacturing, quality and corporate efficiency and will report to David Hung, M.D., founder, president and chief executive officer of Medivation. Ms. McCourt has more than two decades of wide-ranging executive management leadership experience at some of the world's most innovative biopharmaceutical companies. Most recently, she was a vice president in U.S. commercial operations for Amgen Inc., one of the world's leading independent biotechnology companies, where she was part of the team that drove the Launch Readiness for multiple assets and led the Organized Customer Team. She also served as the vice president/general manager of the Bone Health & Primary Care Business Unit. Previously, she was the chief operating officer for AstraZeneca US with leadership and P & L accountability for AstraZeneca's largest market with $13 billion in sales. Her responsibilities included oversight and direct report of all U.S. commercial functions, including medical affairs, business development, finance, human resources, legal, operations, payer-government and sales and marketing. During her 12-year tenure at AstraZeneca, Ms. McCourt was President & CEO of AstraZeneca Canada Inc. and also held the following roles in AstraZeneca Pharmaceuticals LP: Vice President US Business Development, Strategy & Launch; Vice President of Business Units; and Vice President Managed Markets, Government & Policy.
Financial terms:
Latest news:
